# A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder

> **NCT00122850** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 480 (—)

## Conditions studied

- Anxiety Disorders

## Interventions

- **DRUG:** Duloxetine
- **DRUG:** venlafaxine
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00122850
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** —
- **Final completion:** 2005-11
- **Target enrollment:** 480 (—)
- **Last updated:** 2007-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00122850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00122850, "A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00122850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*